- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06251687
Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis
Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis:a Multicenter Prospective Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with PPF, ≥18 years of age, unclassified ILD, HRCT ≤3 months, forced vital capacity (FVC)≥50% predicted value, pulmonary carbon monoxide diffusion (DLCO)≥35% predicted value, echocardiography ≤12 months, estimated pulmonary systolic blood pressure ≤40 mmHg, Body mass index (BMI)≤35 kg/m2.
Exclusion Criteria:
Patients with platelet counts below 50,000×109/L or International Normalized ratio of prothrombin time (INR) above 1.5 are not eligible for TBLC
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transbronchial Cryobiopsy (TBLC)
Transbronchial lung cryobiopsy (TBLC) has been increasingly utilised to diagnose diffuse parenchymal lung diseases
|
Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases
|
Active Comparator: Transbronchial Lung Biopsy (TBLB)
Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
|
Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the diagnostic performance of transbronchial cryobiopsy(TBLC)
Time Frame: 1 month after transbronchial cryobiopsy
|
the sensitivity and specificity of transbronchial cryobiopsy(TBLC)in suspected progressive pulmonary fibrosis
|
1 month after transbronchial cryobiopsy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the safety of transbronchial cryobiopsy(TBLC)
Time Frame: 7 days and 1 month after transbronchial cryobiopsy
|
The occurence of short-term procedure-related complications, including Bleeding, pneumothorax, death, etc
|
7 days and 1 month after transbronchial cryobiopsy
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZRJY2021-BJ08-03-01-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingIdiopathic Pulmonary Fibrosis | Pulmonary Disease | Pulmonary MedicineFrance
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Centre Hospitalier Universitaire de NiceRecruitingPulmonary Disease, Chronic Obstructive | Interstitial Pulmonary FibrosisFrance
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Transbronchial Cryobiopsy,TBLC
-
Centre hospitalier de l'Université de Montréal...CompletedTransbronchial Lung CryobiopsyCanada
-
Guangzhou Institute of Respiratory DiseaseUnknownSafety | Transbronchial Cryobiopsy | Freezing Time | Diagnostic YieldChina
-
ShiYue LiRecruitingDiagnosis | Complication RateChina
-
Shanghai Chest HospitalFirst Affiliated Hospital of Chongqing Medical UniversityUnknown
-
Guangzhou Institute of Respiratory DiseaseUnknownDiffuse Parenchymal Lung DiseasesChina
-
Pusan National University HospitalActive, not recruitingLung NoduleKorea, Republic of
-
Lithuanian University of Health SciencesCompleted
-
KU LeuvenNot yet recruiting
-
China-Japan Friendship HospitalRecruitingAcute Respiratory Distress Syndrome | Acute Respiratory FailureChina
-
Laval UniversityRecruitingInterstitial Lung DiseaseCanada